Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4][16] Core Views - The company's performance in 2024 is expected to meet forecasts, with a continued recovery in core business operations [4][5] - Revenue for 2024 is projected to be between 4.2 billion to 4.3 billion yuan, representing a year-over-year increase of 1.77% to 4.19% [4] - The net profit attributable to shareholders is expected to be between 373 million to 393 million yuan, showing a significant year-over-year growth of 88% to 98% [4] - The company has adjusted its profit forecasts for 2024-2026 due to ongoing compliance work in the domestic medical sector, with net profit estimates of 383 million, 450 million, and 530 million yuan for the respective years [4][5] Financial Performance Summary - The company anticipates a revenue of 40.5 billion to 41.3 billion yuan for 2024, excluding isolation protective products, which indicates a year-over-year growth of 14.28% to 16.54% [5] - The gross margin for 2024 is expected to be between 33.58% and 34.38%, reflecting an increase of 0.82 to 1.62 percentage points year-over-year [5] - The company has achieved a significant recovery in its core business, with a notable increase in revenue and profitability after excluding the impact of isolation protective products [5][6] Market Position and Brand Strength - The company has strengthened its market position with over 98% coverage in top chain pharmacies and more than 200,000 stores as of the first half of 2024 [6] - The company has also established a strong online presence with 15 e-commerce stores and over 9.15 million followers across platforms [6] - Recognition as a top home medical device brand in the 2024 Health Industry Brand List and winning the Xipu Gold Award further enhances its brand influence [6]

Core Viewpoint - Zhendemedical (603301) announced a profit forecast for 2024, expecting a net profit between 373 million to 393 million yuan, representing a year-on-year growth of 88.00% to 98.09% [1] Group 1: Company Performance - The stock price of Zhendemedical closed at 21.44 yuan, with a slight increase of 0.28% on the announcement day [1] - The trading volume was 23.23 million yuan, with a turnover rate of 0.41% [1] - Over the past five days, the stock has increased by 2.10% [1] Group 2: Market Reaction - A statistical analysis showed that 72.26% of stocks with a profit forecast increase of over 50% experienced a price increase on the announcement day [1] - Among these stocks, 20 companies hit the daily price limit on the announcement day [1] - Over the following five days, 83.87% of these stocks saw price increases [1] Group 3: Capital Flow - On the announcement day, Zhendemedical experienced a net inflow of 370,900 yuan in main funds, while there was a net outflow of 238,900 yuan over the past five days [1] - As of January 20, the margin balance was 36.91 million yuan, with a financing balance of 36.64 million yuan, reflecting a 0.86% increase from the previous trading day [1] - The financing balance has decreased by 3.30% over the past five days [1]

Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between RMB 373 million and RMB 393 million, representing an increase of 88.00% to 98.09% compared to the previous year[2]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between RMB 303 million and RMB 323 million, an increase of 59.82% to 70.37% year-on-year[3]. - The company anticipates total revenue for 2024 to be between RMB 4.2 billion and RMB 4.3 billion, reflecting a growth of 1.77% to 4.19% compared to the previous year[6]. Revenue Breakdown - Revenue from isolation protective products is expected to decline to between RMB 150 million and RMB 170 million, a decrease of 70.85% to 74.28% from RMB 583.2 million in the previous year[7]. - Revenue excluding isolation protective products is projected to be between RMB 4.05 billion and RMB 4.13 billion, an increase of 14.28% to 16.54% compared to RMB 3.54 billion in the previous year[7]. Gross Profit Expectations - The gross profit from isolation protective products is expected to be between RMB 60 million and RMB 70 million, down 74.20% to 77.89% from RMB 271.34 million last year[7]. - The gross profit from core business excluding isolation protective products is projected to be between RMB 1.36 billion and RMB 1.42 billion, an increase of 17.13% to 22.30% compared to RMB 1.1611 billion in the previous year[7]. Non-Operating Gains and Impairment Tests - The increase in non-operating gains is expected to be approximately RMB 60 million due to asset disposal gains from land use rights[6]. - The company has conducted impairment tests on inventory and production equipment, leading to a low performance base for 2023[6]. Performance Forecast Accuracy - There are no significant uncertainties that could affect the accuracy of this performance forecast[9].

证券代码：603301 证券简称：振德医疗 公告编号：2024-030 振德医疗用品股份有限公司 关于公司第二期员工持股计划第二个解锁期解锁条 件未达成暨锁定期届满的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于 2024 年 12 月 13 日召开了第三届董事会第十九次会议、第三届监事会第十六次 会议审议通过《关于公司第二期员工持股计划第二个解锁期解锁条件 未达成情况的议案》，具体情况如下： 一、第二期员工持股计划的基本情况 公司分别于 2022 年 9 月 30 日、2022 年 10 月 20 日召开第三届 董事会第四次会议和 2022 年第二次临时股东大会，审议通过了《关 于<公司第二期员工持股计划（草案）>及其摘要的议案》等相关议案， 同意实施公司第二期员工持股计划，具体内容详见公司于 2022 年 10 月1日、2022 年10月21日在上海证券交易所网站（www.sse.com.cn） 披露的公告。 2022 年 12 月 14 日，公司收到中国证券登记结算有 ...

Investment Rating - The report maintains a "Strong Buy" rating for ZhenDe Medical (603301) with a target price of 34 CNY [1][3] Core Views - Revenue in Q3 2024 reached 1.083 billion CNY, a 19.92% YoY increase, with net profit attributable to shareholders surging 131.73% YoY to 146 million CNY [1] - Excluding exchange rate impacts, adjusted net profit grew over 40% YoY in Q3 2024 [1] - The company's overseas business recovered strongly, with Q3 2024 revenue increasing 24.36% YoY to 645 million CNY [1] - Domestic hospital channel revenue grew 20.99% YoY in Q3 2024, reaching 278 million CNY [1] Financial Performance Revenue Breakdown - Regular business revenue (excluding protective products) grew 21.05% YoY in Q3 2024 to 1.054 billion CNY [1] - Protective products revenue declined 10.56% YoY to 29 million CNY in Q3 2024 [1] - Domestic business revenue increased 13.52% YoY to 432 million CNY in Q3 2024 [1] Profitability - Gross margin improved to 33.77% in Q3 2024, up 0.45 percentage points YoY [1] - Net profit margin surged to 13.87% in Q3 2024, a 6.57 percentage point increase YoY [1] - Asset disposal contributed approximately 93 million CNY to Q3 2024 net profit [1] Cost Structure - Sales expense ratio decreased to 7.53% in Q3 2024, down 0.43 percentage points YoY [1] - Management expense ratio fell to 12.20% in Q3 2024, a 0.75 percentage point reduction YoY [1] - R&D expense ratio increased to 3.36% in Q3 2024, up 0.24 percentage points YoY [1] Financial Forecasts - Revenue is projected to grow from 4.466 billion CNY in 2024E to 6.024 billion CNY in 2026E [2] - Net profit attributable to shareholders is expected to increase from 466 million CNY in 2024E to 618 million CNY in 2026E [2] - EPS is forecasted to rise from 1.75 CNY in 2024E to 2.32 CNY in 2026E [2] - PE ratio is estimated to decline from 14x in 2024E to 10x in 2026E [2] Valuation - The DCF model suggests a total valuation of 9 billion CNY for the company [1] - The target price of 34 CNY implies a 43.7% upside potential from the current price of 23.66 CNY [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 31.68 yuan for the next 6 months [1] Core Views - The company's Q3 2024 performance met expectations, with overseas destocking effects eliminated [1] - Revenue for the first three quarters of 2024 was 3.13 billion yuan (-2.6% YoY), while net profit attributable to the parent company was 310 million yuan (+2.3% YoY) [1] - Q3 2024 single-quarter revenue reached 1.08 billion yuan (+19.9% YoY), with net profit attributable to the parent company at 150 million yuan (+131.7% YoY) [1] - The high net profit growth in Q3 2024 was mainly due to asset disposal gains of nearly 100 million yuan [2] Business Performance - Excluding isolation protection products, Q3 2024 revenue was 1.054 billion yuan (+21.1% YoY) [2] - Isolation protection products (masks, protective clothing, isolation gowns, antigen test kits) revenue was 30 million yuan (-10.6% YoY) [2] - Revenue growth was driven by overseas business and domestic hospital business, with destocking effects gradually decreasing [2] - Domestic hospital channel performance was strong, with increased product portfolio and hospital coverage [3] - Overseas sales mainly follow OEM/ODM models, with long-term strategic partnerships established with multiple well-known medical device brands [3] Strategic Development - The company has accelerated M&A activities to enrich domestic product lines and expand overseas channels [3] - In April 2023, the company acquired Jiangsu Inbase to supplement its therapy product line with pre-filled catheter flush syringes [3] - In late 2022, the company acquired UK subsidiary Rocialle Healthcare Limited to integrate community medical distribution resources [3] Financial Forecast - The company is expected to achieve net profit attributable to the parent company of 420 million, 470 million, and 570 million yuan in 2024-2026 [4] - Revenue growth rates are projected at 5.74%, 16.89%, and 16.27% for 2024-2026 [5] - EPS is forecasted to be 1.57, 1.76, and 2.16 yuan for 2024-2026 [5] - ROE is expected to be 7.76%, 7.98%, and 8.90% for 2024-2026 [5] Business Segment Analysis - Surgical infection control: Expected revenue growth of 20%, 18%, 18% for 2024-2026, with gross margin improving to 35% [8] - Basic wound care: Expected revenue growth of 10%, 13%, 13% for 2024-2026, with gross margin improving to 26.5% [8] - Pressure therapy and fixation: Expected revenue growth of 20%, 18%, 18% for 2024-2026, with gross margin at 42% [8] - Ostomy and modern wound care: Expected revenue growth of 25%, 25%, 20% for 2024-2026, with gross margin at 47% [8] - Infection protection: Expected revenue decline of 60% in 2024, followed by 5% growth in 2025-2026, with gross margin at 36% [9]

Investment Rating - The investment rating for the company is "Outperform the Market" [3][10] Core Views - The company reported a revenue growth of 20% in Q3 2024, with a significant increase in net profit due to asset disposal gains and improved domestic hospital line business [1][3] - The company has adjusted its revenue forecasts for 2024-2026, expecting revenues of 44.0 billion, 51.8 billion, and 60.7 billion respectively, with corresponding net profits of 4.0 billion, 5.1 billion, and 6.4 billion [1][3] - The gross margin has shown a slight increase to 33.77%, attributed to a better revenue mix, while financial expenses have risen due to exchange losses [1][3] Summary by Sections Financial Performance - In Q3 2024, the company achieved a revenue of 10.83 billion (up 19.92% YoY) and a net profit of 1.46 billion (up 131.73% YoY) [1] - For the first three quarters of 2024, total revenue was 31.25 billion (down 2.61% YoY) and net profit was 3.07 billion (up 2.31% YoY) [1][2] Revenue Breakdown - The company's conventional business (excluding isolation protective products) generated 10.54 billion in Q3 2024, a 21.05% increase YoY [1] - Overseas business revenue reached 6.45 billion (up 24.36% YoY), while domestic business revenue was 4.32 billion (up 13.52% YoY) [1] Cost and Margin Analysis - The gross margin improved to 33.77% (up 0.45 percentage points), driven by a higher proportion of modern wound dressings and surgical infection control products [1] - Financial expense ratio increased to 2.23% (up 2.69 percentage points), primarily due to increased exchange losses [1] Future Outlook - The company anticipates gradual improvement in performance as the impact of overseas inventory clearance diminishes and domestic industry adjustments ease [1][3] - The adjusted profit forecasts reflect a strong recovery trajectory, with expected net profit growth rates of 101%, 28%, and 24% for the years 2024, 2025, and 2026 respectively [1][3]

Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,082,970,366.62, representing a year-on-year increase of 19.92%[2] - Net profit attributable to shareholders for Q3 2024 was ¥146,351,133.85, a significant increase of 131.73% compared to the same period last year[2] - The basic and diluted earnings per share for Q3 2024 were both ¥0.55, reflecting a year-on-year increase of 129.17%[4] - Total operating revenue for the first three quarters of 2024 was CNY 3,125,390,090.31, a decrease of 2.61% compared to CNY 3,209,194,823.07 in the same period of 2023[20] - Net profit for the first three quarters of 2024 was CNY 317,474,354.86, an increase of 2.38% compared to CNY 308,745,291.11 in the same period of 2023[21] - Earnings per share for the first three quarters of 2024 were CNY 1.15, compared to CNY 1.13 in the same period of 2023[22] - Comprehensive income for the first three quarters of 2024 was CNY 367,041,293.44, compared to CNY 323,240,452.44 in the same period of 2023[22] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥7,873,442,974.15, an increase of 8.35% from the end of the previous year[4] - Total liabilities as of the end of the third quarter of 2024 amounted to CNY 2,036,039,313.17, an increase of 22.49% from CNY 1,662,319,359.19 at the end of the previous year[20] - Total equity attributable to shareholders of the parent company was CNY 5,582,058,548.97, an increase of 4.05% from CNY 5,365,596,147.58 in the previous year[20] - The company's total assets reached CNY 7,873,442,974.15, an increase from CNY 7,266,719,674.70 at the end of the previous year[20] Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 39.31% to ¥159,518,116.70 compared to the same period last year[4] - In the first three quarters of 2024, the net cash flow from operating activities was ¥159,518,116.70, a decrease of 39.4% compared to ¥262,852,224.14 in the same period of 2023[25] - Total cash inflow from operating activities was ¥3,382,595,024.60, down from ¥3,823,930,847.44, representing a decline of 11.5% year-over-year[25] - Cash outflow from operating activities totaled ¥3,223,076,907.90, compared to ¥3,561,078,623.30 in the previous year, indicating a decrease of 9.5%[25] - The cash flow from investment activities showed a net outflow of ¥639,071,697.05, an improvement from a net outflow of ¥1,055,233,440.43 in the same period last year[25] - Cash inflow from investment activities was ¥510,640,483.98, significantly higher than ¥102,670,916.39 in the previous year[25] - Cash inflow from financing activities was ¥1,419,260,000.00, up from ¥585,065,805.00, marking an increase of 142.6% year-over-year[25] - The net cash flow from financing activities was ¥234,402,342.05, a turnaround from a net outflow of ¥74,313,386.63 in the same period of 2023[25] - The ending balance of cash and cash equivalents was ¥799,490,399.41, down from ¥1,205,615,108.09 in the previous year[25] - The company reported a cash inflow of ¥450,000,000.00 from the recovery of investments, compared to ¥100,000,000.00 in the same period last year[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,529 shares[10] - Zhejiang Zhendai Holdings Co., Ltd. holds 132,739,480 shares, accounting for 49.82% of the total shares[10] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 2.66%, an increase of 1.54 percentage points compared to the previous year[4] - The company reported a decrease of 20.59% in net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period[8] - Research and development expenses for the first three quarters of 2024 were CNY 98,872,971.89, a decrease from CNY 110,447,381.62 in the same period of 2023[20] - The company reported a significant increase in other comprehensive income after tax, totaling CNY 49,566,938.58 compared to CNY 14,495,161.33 in the previous year[21] - The company has not adopted new accounting standards or interpretations affecting the financial statements for the year[26] Business Operations - The overseas main business revenue for Q3 2024 was ¥645 million, an increase of 24.36% year-on-year, indicating a recovery in international operations[7] - The revenue from domestic hospital lines reached ¥278 million, showing a growth of 20.99% compared to the same period last year[7] - The company recognized a gain from the disposal of assets due to the acquisition of land use rights and properties, contributing positively to net profit[7] - The company signed an asset acquisition agreement for state-owned land use rights and buildings, with a total compensation amount of RMB 297.81 million, which is expected to increase net profit by approximately RMB 9.3 million[15] Current Assets and Liabilities - Current assets total RMB 3,113.70 million, up from RMB 2,719.81 million at the end of 2023, reflecting a growth of approximately 14.5%[16] - The company's cash and cash equivalents decreased to RMB 806.65 million from RMB 1,051.79 million, a decline of about 23.3%[16] - Accounts receivable increased to RMB 702.18 million from RMB 539.65 million, representing a growth of approximately 30.2%[16] - Inventory increased to RMB 820.81 million from RMB 800.81 million, showing a slight increase of about 2.5%[16] - The company reported a short-term loan of RMB 451.83 million, up from RMB 220.14 million, indicating an increase of approximately 105.5%[18] - The total non-current assets amount to RMB 4,759.74 million, an increase from RMB 4,546.91 million, reflecting a growth of approximately 4.7%[18]

证券代码：603301 证券简称：振德医疗 公告编号：2024-029 振德医疗用品股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2024 年 11 月 25 日（星期一）13:00-14:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2024 年 11 月 18 日（星期一）至 11 月 22 日（星 期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日发布公司 2024 年第三季度报告。为便于广大投资者更全 面深入地了解公司 2024 年三季度经营成果、财务状况，公司计划于 2024 年 11 月 25 ...

证券代码：603301 证券简称：振德医疗 公告编号：2024-026 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 控股股东的一致行动人持股的基本情况 振德医疗用品股份有限公司控股股东的一致行动人 减持股份计划提前终止的公告 截至本公告披露日，振德医疗用品股份有限公司（以下简称"公司"）股东 许昌振德园林绿化工程有限公司（以下简称"许昌园林"，系控股股东浙江振德 控股有限公司全资子公司）持有公司股份 11,773,940 股，占公司总股本的 4.42%。 公司控股股东浙江振德控股有限公司、实际控制人鲁建国、沈振芳与许昌园林系 一致行动人，合计持有公司股份 157,748,066 股，占公司总股本的 59.20%。 减持计划的实施结果情况 公司于 2024 年 10 月 11 日收到许昌园林出具的《关于提前终止集中竞价、 大宗交易减持股份计划的告知函》，许昌园林决定终止本次股份减持计划（详见 公司于 2024 年 10 月 9 日披露的《振德医疗控股股东的一致行动人减持股份计划 公告》（公告编号：2 ...